Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein

Hyun Jung Kim, Chang Hoon Shin, Chan Wha Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The formulation of new biotherapeutics without human serum albumin (HSA) could decrease the potential risk of blood-transmitted diseases and those caused by infectious viruses and other pathogens. In the present study, arginine was examined as a potential alternative to HAS, and bovine lactoferrin (bLf) was used as a representative model glycoprotein since bLf has potential immunomodulatory and antiviral activity. The optimal formulation for the mixture was determined to be 10mM arginine, 15% (w/v) trehalose, and 0.02% (v/v) Tween 80, using a statistical analysis program, Minitab. Analyses were performed using reverse-phase high-performance liquid chromatography (HPLC) and SDS-PAGE. The blf HSA-free formulations lost only 12-20% of blf compared with 46% for control (without additives) after 28 d of storage. Based on long-term stability studies, the HSA-free formulation developed in this study had a stronger effect on the stability of bLf (1.4-fold) than HSA formulation under various storage conditions over 6 months.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalBioscience, Biotechnology and Biochemistry
Volume73
Issue number1
DOIs
Publication statusPublished - 2009 Feb 2

Fingerprint

Lactoferrin
Serum Albumin
Arginine
Glycoproteins
Stabilization
Liquids
Proteins
Trehalose
Polysorbates
Hematologic Diseases
High performance liquid chromatography
Pathogens
Reverse-Phase Chromatography
Viruses
Antiviral Agents
Polyacrylamide Gel Electrophoresis
Statistical methods
Blood
High Pressure Liquid Chromatography

Keywords

  • Arginine
  • Human serum albumin
  • Lactoferrin
  • Liquid formulation
  • Stabilizing agent

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Analytical Chemistry
  • Organic Chemistry
  • Applied Microbiology and Biotechnology

Cite this

Stabilization of glycoprotein liquid formulation using arginine : A study with lactoferrin as a model protein. / Kim, Hyun Jung; Shin, Chang Hoon; Kim, Chan Wha.

In: Bioscience, Biotechnology and Biochemistry, Vol. 73, No. 1, 02.02.2009, p. 61-66.

Research output: Contribution to journalArticle

@article{c6757a1dc2644919a10b3588fe93ce90,
title = "Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein",
abstract = "The formulation of new biotherapeutics without human serum albumin (HSA) could decrease the potential risk of blood-transmitted diseases and those caused by infectious viruses and other pathogens. In the present study, arginine was examined as a potential alternative to HAS, and bovine lactoferrin (bLf) was used as a representative model glycoprotein since bLf has potential immunomodulatory and antiviral activity. The optimal formulation for the mixture was determined to be 10mM arginine, 15{\%} (w/v) trehalose, and 0.02{\%} (v/v) Tween 80, using a statistical analysis program, Minitab. Analyses were performed using reverse-phase high-performance liquid chromatography (HPLC) and SDS-PAGE. The blf HSA-free formulations lost only 12-20{\%} of blf compared with 46{\%} for control (without additives) after 28 d of storage. Based on long-term stability studies, the HSA-free formulation developed in this study had a stronger effect on the stability of bLf (1.4-fold) than HSA formulation under various storage conditions over 6 months.",
keywords = "Arginine, Human serum albumin, Lactoferrin, Liquid formulation, Stabilizing agent",
author = "Kim, {Hyun Jung} and Shin, {Chang Hoon} and Kim, {Chan Wha}",
year = "2009",
month = "2",
day = "2",
doi = "10.1271/bbb.80475",
language = "English",
volume = "73",
pages = "61--66",
journal = "Bioscience, Biotechnology and Biochemistry",
issn = "0916-8451",
publisher = "Japan Society for Bioscience Biotechnology and Agrochemistry",
number = "1",

}

TY - JOUR

T1 - Stabilization of glycoprotein liquid formulation using arginine

T2 - A study with lactoferrin as a model protein

AU - Kim, Hyun Jung

AU - Shin, Chang Hoon

AU - Kim, Chan Wha

PY - 2009/2/2

Y1 - 2009/2/2

N2 - The formulation of new biotherapeutics without human serum albumin (HSA) could decrease the potential risk of blood-transmitted diseases and those caused by infectious viruses and other pathogens. In the present study, arginine was examined as a potential alternative to HAS, and bovine lactoferrin (bLf) was used as a representative model glycoprotein since bLf has potential immunomodulatory and antiviral activity. The optimal formulation for the mixture was determined to be 10mM arginine, 15% (w/v) trehalose, and 0.02% (v/v) Tween 80, using a statistical analysis program, Minitab. Analyses were performed using reverse-phase high-performance liquid chromatography (HPLC) and SDS-PAGE. The blf HSA-free formulations lost only 12-20% of blf compared with 46% for control (without additives) after 28 d of storage. Based on long-term stability studies, the HSA-free formulation developed in this study had a stronger effect on the stability of bLf (1.4-fold) than HSA formulation under various storage conditions over 6 months.

AB - The formulation of new biotherapeutics without human serum albumin (HSA) could decrease the potential risk of blood-transmitted diseases and those caused by infectious viruses and other pathogens. In the present study, arginine was examined as a potential alternative to HAS, and bovine lactoferrin (bLf) was used as a representative model glycoprotein since bLf has potential immunomodulatory and antiviral activity. The optimal formulation for the mixture was determined to be 10mM arginine, 15% (w/v) trehalose, and 0.02% (v/v) Tween 80, using a statistical analysis program, Minitab. Analyses were performed using reverse-phase high-performance liquid chromatography (HPLC) and SDS-PAGE. The blf HSA-free formulations lost only 12-20% of blf compared with 46% for control (without additives) after 28 d of storage. Based on long-term stability studies, the HSA-free formulation developed in this study had a stronger effect on the stability of bLf (1.4-fold) than HSA formulation under various storage conditions over 6 months.

KW - Arginine

KW - Human serum albumin

KW - Lactoferrin

KW - Liquid formulation

KW - Stabilizing agent

UR - http://www.scopus.com/inward/record.url?scp=58849115460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849115460&partnerID=8YFLogxK

U2 - 10.1271/bbb.80475

DO - 10.1271/bbb.80475

M3 - Article

C2 - 19129655

AN - SCOPUS:58849115460

VL - 73

SP - 61

EP - 66

JO - Bioscience, Biotechnology and Biochemistry

JF - Bioscience, Biotechnology and Biochemistry

SN - 0916-8451

IS - 1

ER -